HY-U00425 Search Results


mice  (MedChemExpress)
93
MedChemExpress mice
Mice, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mice/product/MedChemExpress
Average 93 stars, based on 1 article reviews
mice - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
bf738735  (MedChemExpress)
93
MedChemExpress bf738735
(a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds <t>BF738735,</t> Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).
Bf738735, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bf738735/product/MedChemExpress
Average 93 stars, based on 1 article reviews
bf738735 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
kinase inactive ki egf receptor re expression  (MedChemExpress)
90
MedChemExpress kinase inactive ki egf receptor re expression
(a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds <t>BF738735,</t> Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).
Kinase Inactive Ki Egf Receptor Re Expression, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kinase inactive ki egf receptor re expression/product/MedChemExpress
Average 90 stars, based on 1 article reviews
kinase inactive ki egf receptor re expression - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
protac errα ligand 1  (MedChemExpress)
N/A
   Buy from Supplier

Image Search Results


(a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds BF738735, Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).

Journal: bioRxiv

Article Title: A high-throughput cell-based platform for Rhinovirus C research and antiviral drug discovery

doi: 10.1101/2025.10.28.680218

Figure Lengend Snippet: (a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds BF738735, Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).

Article Snippet: Rupintrivir (Sigma-Aldrich PZ0315), BF738735 (MedChemExpress HY-U00426), Pirodavir (Sigma-Aldrich SML1818), and Vapendavir (Cayman 30546) were prepared as 10 mM DMSO stocks.

Techniques: Infection, Antiviral Assay, Inhibition, Virus, Control

(a) Schematic of 384-well format antiviral assay procedure. Created with BioRender. (b) Assay robustness in 384-well format across RV-A16, RV-B14, and RV-C15a-mGL assays using >100 pre-spotted plates with reference compounds. (c) Distribution of pIC 50 values (-log 10 IC 50 , M) for BF738735 and Rupintrivir in the RV-C15a-mGL assay. Each dot represents an individual run; boxes indicate median, interquartile range (IQR), and whiskers (1.5x IQR).

Journal: bioRxiv

Article Title: A high-throughput cell-based platform for Rhinovirus C research and antiviral drug discovery

doi: 10.1101/2025.10.28.680218

Figure Lengend Snippet: (a) Schematic of 384-well format antiviral assay procedure. Created with BioRender. (b) Assay robustness in 384-well format across RV-A16, RV-B14, and RV-C15a-mGL assays using >100 pre-spotted plates with reference compounds. (c) Distribution of pIC 50 values (-log 10 IC 50 , M) for BF738735 and Rupintrivir in the RV-C15a-mGL assay. Each dot represents an individual run; boxes indicate median, interquartile range (IQR), and whiskers (1.5x IQR).

Article Snippet: Rupintrivir (Sigma-Aldrich PZ0315), BF738735 (MedChemExpress HY-U00426), Pirodavir (Sigma-Aldrich SML1818), and Vapendavir (Cayman 30546) were prepared as 10 mM DMSO stocks.

Techniques: Antiviral Assay

(a) Workflow of RV-C15a-mGL HTS campaign in 384-well format. (b) Scatterplot summarizing primary screening at 10 µM and three reference compounds BF738735, Pirodavir, and Rupintrivir (yellow). Compounds with inhibition > 60% and viability > 90% are highlighted in green. (c) Assay performance across 32 HTS plates. VC and CC are plotted against the left Y-axis in % infection, while Z’ is plotted against the right Y-axis. VC, virus control. CC, cell control. (d) Inhibition and viability curves for five top hit compounds from mini dose-response assays (0.2 – 25 µM, n=4). (e) Distribution of IC 50 , CC 50 , and selective index (SI = CC 50 /IC 50 ) values for 19 confirmed hits from mini dose-response assays. Five top hits (SI > 7) are highlighted in green.

Journal: bioRxiv

Article Title: A high-throughput cell-based platform for Rhinovirus C research and antiviral drug discovery

doi: 10.1101/2025.10.28.680218

Figure Lengend Snippet: (a) Workflow of RV-C15a-mGL HTS campaign in 384-well format. (b) Scatterplot summarizing primary screening at 10 µM and three reference compounds BF738735, Pirodavir, and Rupintrivir (yellow). Compounds with inhibition > 60% and viability > 90% are highlighted in green. (c) Assay performance across 32 HTS plates. VC and CC are plotted against the left Y-axis in % infection, while Z’ is plotted against the right Y-axis. VC, virus control. CC, cell control. (d) Inhibition and viability curves for five top hit compounds from mini dose-response assays (0.2 – 25 µM, n=4). (e) Distribution of IC 50 , CC 50 , and selective index (SI = CC 50 /IC 50 ) values for 19 confirmed hits from mini dose-response assays. Five top hits (SI > 7) are highlighted in green.

Article Snippet: Rupintrivir (Sigma-Aldrich PZ0315), BF738735 (MedChemExpress HY-U00426), Pirodavir (Sigma-Aldrich SML1818), and Vapendavir (Cayman 30546) were prepared as 10 mM DMSO stocks.

Techniques: Inhibition, Infection, Virus, Control